Non-invasive Assessment of Neurovascular Coupling After Aneurysmal Subarachnoid Hemorrhage: A Prospective Observational Trial Using Retinal Vessel Analysis

Walid Albanna 1,2*, Catharina Conzen 1†, Miriam Weiss 1, Katharina Seyfried 1, Konstantin Kotliar 3, Tobias Philip Schmidt 1, David Kuerten 4, Jürgen Hescheler 2, Anne Bruecken 5, Arno Schmidt-Trucksäss 6, Felix Neumaier 1, Martin Wiesmann 7, Hans Clusmann 1 and Gerrit Alexander Schubert 1

Objective: Delayed cerebral ischemia (DCI) is a common complication after aneurysmal subarachnoid hemorrhage (aSAH) and can lead to infarction and poor clinical outcome. The underlying mechanisms are still incompletely understood, but animal models indicate that vasoactive metabolites and inflammatory cytokines produced within the subarachnoid space may progressively impair and partially invert neurovascular coupling (NVC) in the brain. Because cerebral and retinal microvasculature are governed by comparable regulatory mechanisms and may be connected by perivascular pathways, retinal vascular changes are increasingly recognized as a potential surrogate for altered NVC in the brain. Here, we used non-invasive retinal vessel analysis (RVA) to assess microvascular function in aSAH patients at different times after the ictus.

Methods: Static and dynamic RVA were performed using a Retinal Vessel Analyzer (IMEDOS Systems GmbH, Jena) in 70 aSAH patients during the early (d0−4), critical (d5−15), late (d16−23) phase, and at follow-up (f/u > 6 weeks) after the ictus. For comparison, an age-matched cohort of 42 healthy subjects was also included in the study. Vessel diameters were quantified in terms of the central retinal arterial and venous equivalent (CRAE, CRVE) and the retinal arterio-venous-ratio (AVR). Vessel responses to flicker light excitation (FLE) were quantified by recording the maximum arterial and venous dilation (MAD, MVD), the time to 30% and 100% of maximum dilation (tMAD30, tMVD30; tMAD, tMVD, resp.), and the arterial and venous area under the curve (AUCart, AUCven) during the FLE. For subgroup analyses, patients were stratified according to the development of DCI and clinical outcomes after 12 months.
Results: Vessel diameter (CRAE, CRVE) was significantly smaller in aSAH patients and showed little change throughout the whole observation period \( (p < 0.0001\) vs. control for all time periods examined). In addition, aSAH patients exhibited impaired arterial but not venous responses to FLE, as reflected in a significantly lower MAD \([2.2 (1.0–3.2)\%\) vs. \(3.6 (2.6–5.6)\%\) in control subjects, \(p = 0.0016\)] and AUCart \([21.5 (9.4–35.8)\%\) vs. \(51.4 (32.5–69.7)\%\) in control subjects, \(p = 0.0001\)] on \(d_{0–4}\). However, gradual recovery was observed during the first 3 weeks, with close to normal levels at follow-up, when MAD and AUCart amounted to \(3.0 (2.0–5.0)\%\) \(p = 0.141\) vs. control, \(p = 0.0321\) vs. \(d_{5–15}\) and \(44.5 (23.2–61.1)\%\) \(p = 0.138\) vs. control, \(p < 0.01\) vs. \(d_{0–4}\) & \(d_{5–15}\).

Finally, patients with clinical deterioration (DCI) showed opposite changes in the kinetics of arterial responses during early and late phase, as reflected in a significantly lower tMAD30 on \(d_{0–4}\) \(4.0 (3.0–6.8)\) s vs. \(7.0 (5.0–8.0)\) s in patients without DCI, \(p = 0.022\) and a significantly higher tMAD on \(d_{16–23}\) \(24.0 (21.0–29.3)\) s vs. \(18.0 (14.0–21.0)\) s in patients without DCI, \(p = 0.017\).

Conclusion: Our findings confirm and extend previous observations that aSAH results in sustained impairments of NVC in the retina. DCI may be associated with characteristic changes in the kinetics of retinal arterial responses. However, further studies will be required to determine their clinical implications and to assess if they can be used to identify patients at risk of developing DCI.

Trial Registration: ClinicalTrials.gov Identifier: NCT04094155.

Keywords: aneurysmal subarachnoid hemorrhage, cerebral infarction, delayed cerebral ischemia, microvascular function, neurovascular coupling, retinal vessel analysis

INTRODUCTION

Aneurysmal subarachnoid hemorrhage (aSAH) due to sudden rupture of a cerebral aneurysm is responsible for only 5–7% of all stroke events (1) but is associated with a fatality rate of almost 50%, accounting for up to 20% of all cerebrovascular-related deaths (2). Owing to a complex pathophysiology that involves early and delayed forms of brain injury, a significant number of patients surviving aSAH remain disabled with or without compromise detected on detailed neuropsychological testing. Only 10% of patients recover completely. The most common complication responsible for long-term impairments is delayed cerebral ischemia (DCI), which is typically observed during the first two or at most 3 weeks after aSAH onset and is associated with the appearance of a new focal neurologic deficit or a persistent decline in the patient’s Glasgow Coma Scale score (3). Although traditionally attributed to vasoconstriction of large caliber proximal vessels (i.e., angiographic vasospasm) secondary to degradation of subarachnoid blood and intrathecal immune activation, more recent findings also point to a critical role of microvascular dysfunction (4–7). In particular, several studies performed in animal models have demonstrated a progressive impairment and partial inversion of cerebral neurovascular coupling (NVC) (8–10), the process responsible for adjusting local cerebral blood flow (CBF) to regionally heterogeneous changes in metabolic demand due to neuronal activation. While there is evidence for similar impairment in human aSAH patients (11–13), clinical assessment of NVC remains a diagnostic challenge that is usually achieved through invasive CBF measurements or highly specialized and expensive functional imaging techniques. An alternative approach to evaluate NVC is to measure microvascular responses in the retina, an embryological part of the central nervous system that can be assessed non-invasively by retinal vessel analysis (RVA). Because cerebral and retinal microvasculature bear a close anatomical correlation and are governed by common regulatory mechanisms, retinal vascular changes are increasingly recognized as potential screening option for altered NVC in the brain (14, 15). For example, a potential role of RVA for predicting cerebrovascular changes has previously been shown in elderly adults (16, 17), after coarctation repair (18) and in patients with diabetes (19) or Alzheimer’s disease (20). During aSAH, the sudden rise of intracranial pressure often forces subarachnoid blood into the pre-retinal space (21), which may expose retinal micro-vessels to the same blood degradation products and inflammatory cytokines thought to be responsible for microvascular dysfunction in the brain. In addition, recent discovery of a cerebral and retinal glymphatic system (22) argues for the existence of perivascular pathways through which vasoactive agents formed in the subarachnoid space may also directly reach the retinal microvasculature. We have previously demonstrated the feasibility of RVA in aSAH patients (23) and provided first evidence for retinal vasoconstriction and signs of impaired NVC in these patients compared to healthy control.
subjects (11). In this prospective study on a larger cohort of aSAH patients, we sought to validate our previous findings and evaluate the relationship between potential changes in NVC as detected by RVA and the occurrence of DCI and long-term clinical outcome.

MATERIALS AND METHODS

Patients with aSAH admitted to the Department of Neurosurgery at the RWTH Aachen University Hospital between July 2015 and December 2019 were considered for enrollment into the present study. Patients were selected based on the following inclusion criteria: (1) age ≥18 years, (2) aneurysmal origin of SAH as confirmed by computed tomography (CT) angiography and/or digital subtraction angiography (DSA), (3) absence of intraocular comorbidities or contraindications that would have precluded application of mydriatic agents, and (4) absence of Terson syndrome unless it did not interfere with the analysis of selected retinal vessels. Before enrolment, written informed consent according to the Declaration of Helsinki was obtained from all patients or their legal representatives and the study protocol was approved by the local Research Ethics Committee of the RWTH Aachen University (EK 069/15).

A total of 70 patients with aSAH were prospectively recruited, in whom measurements were performed 0–4 days (early phase: \(d_{0-4}\)), 5–15 days (critical phase: \(d_{5-15}\)), 16–23 days (late phase: \(d_{16-23}\)) and more than 6 weeks (follow-up: f/u) after the ictus. If more than one measurement was available for a given patient in a given phase, all measurements in this phase were averaged to calculate a mean value. For comparison, an age-matched cohort of 42 healthy subjects who were measured by RVA at the Department of Exercise and Health Sciences at the University of Basel was also included in the study.

The clinical severity of aSAH on admission was assessed according to the Hunt and Hess (HH) grading scale and the degree of aneurysmal bleeding was scored according to the modified Fischer (mFS) scale based on CT scans. Patients were treated according to current multidisciplinary consensus guidelines (3, 24, 25). The aneurysm was secured by neurosurgical clipping or endovascular coiling based on an interdisciplinary consensus. Patients received prophylactic nimodipine therapy (180–360 mg per day) unless precluded by hemodynamic instability. All patients were continuously monitored for complications such as delayed cerebral ischemia (DCI), which was considered as a neurological worsening according to the definition by Vergouwen et al. (3) or territorial or watershed hypoperfusion on perfusion CT scans. In analgosedated patients, deterioration in cerebral microdialysis (71 high cut-off catheter, \(\mu\)dialysis, Stockholm, Sweden) or cerebral tissue oxygen saturation (Neurovent PTO, Raumedic AG, Helmbrechts, Germany) were used as surrogates to trigger CT perfusion. First-tier treatment in case of DCI consisted of induced hypertension (>180 mmHg systolic blood pressure) as per institutional protocol. In refractory cases without clinical or neuroradiological improvement but confirmed misery perfusion on CTA or DSA, second-tier rescue therapy by balloon dilatation and/or continuous intra-arterial infusion of nimodipine was considered based on angiographic findings (26, 27). Clinical outcome after 12 months according to the extended Glasgow Outcome Scale (GOS-E) was assessed by an independent investigator based on a telephone interview, clinical investigation in the outpatient clinic or clinical status compiled from the medical reports. A summary of the demographic and clinical data obtained on admission or during in-hospital treatment is provided in Table 1.

Retinal Vessel Analysis

Static and dynamic retinal vessel analyses were performed using a maneuverable Retinal Vessel Analyzer (IMEDOS Systems GmbH, Jena, Germany) as described previously (11, 23). Briefly, after unilateral application of a mydriatic agent (Tropicamide, Mydriaticum Stulln UD, Pharma Stulln GmbH, Stulln, Germany), conscious patients were examined in a sitting position while analgo-sedated patients were examined in supine position with the head and torso partially turned. For assessment of NVC, retinal veins and arteries were focused and the vessel diameters recorded continuously in operator-selected regions of interest located equidistant to the papilla. Measurements were performed with a standard 350 s dynamic vessel analysis protocol comprised of 50 s of baseline recording and three cycles of flicker-light excitation (FLE). For extended analysis the recorded

| TABLE 1 | Demographic and clinical data of control and aSAH patients. |
|-----------------|-----------------|-----------------|
| Patient characteristic | Patients, n (%) | Control, n (%) |
| All patients | 70 (100%) | 42 (100%) |
| Gender | | |
| Female | 51 (73%) | 20 (48%) |
| Male | 19 (27%) | 22 (52%) |
| Age | | |
| | 51 [48–59] yrs | 50 [43–59] yrs |
| Aneurysm location | | |
| Anterior circulation | 53 (76%) | |
| Posterior circulation | 16 (23%) | |
| Both | 1 (1%) | |
| Hunt and hess (HH) grade | | |
| Good grade (HH1–3) | 56 (80%) | |
| Poor grade (HH4–5) | 14 (20%) | |
| Modified fisher (mFS) scale | | |
| Thin blood (mFS0–2) | 34 (49%) | |
| Thick blood (mFS3–4) | 36 (51%) | |
| Treatment modality | | |
| Clipping | 24 (34%) | |
| Coiling | 44 (63%) | |
| Both | 2 (3%) | |
| Delayed cerebral ischemia (DCI) | | |
| DCI | 23 (32%) | |
| DCI-related infarction | 1 (1%) | |
| Outcome | | |
| Favorable (GOS-E1–4) | 64 (92%) | |
| Unfavorable (GOS-E5–8) | 6 (8%) | |

Frontiers in Neurology | www.frontiersin.org 3 June 2021 | Volume 12 | Article 690183
vessel diameters were expressed as percentage of the baseline diameter and plotted as a function of time as described in detail elsewhere (20, 28). To improve the signal-to-noise ratio, the individual response curves obtained for each subject during the three successive cycles of FLE were averaged. In healthy subjects, the typical arterial response curves thus obtained feature primary vasodilation upon initiation of FLE, which reaches a maximum after a characteristic latency and is followed, after termination of vasodilation upon initiation of FLE, which reaches a maximum three successive cycles of FLE were averaged. In healthy subjects, individual response curves obtained for each subject during the

for static retinal vessel analysis (4)

were female and 19 (27%) were male. Twenty-three (32%) of the patients developed delayed cerebral ischemia (DCI), which progressed to infarction in one patient. The clinical outcome after 12 months was favorable (GOS-E5–8) in 64 (92%) and unfavorable (GOS-E1–4) in 6 (8%) of the patients. Retinal vessel analysis (RVA) could be performed in 32, 53, 23, and 40 patients during the early (d0–4), critical (d5–15), late (d16–23) phase, and follow-up, respectively. For comparison, a cohort of 42 healthy subjects with a median age of 50 [43–59] years, of whom 20 (48%) were female and 22 (52%) were male, was also included in the study (Table 1).

**Vessel Diameters**

When compared to control subjects, the arterial diameter, expressed as central retinal arterial equivalent (CRAE), was significantly reduced immediately after aSAH and remained so throughout the whole observation period (p < 0.0001 for all time periods examined), with only a minor, non-significant increase in vessel diameters observed in measurements performed at follow-up (t/u) more than 6 weeks after the ictus (Figure 2A, Table 2). Likewise, the central retinal venous equivalent (CRVE) was significantly reduced in aSAH patients compared to control subjects (p < 0.0001 for all time periods examined) and showed little change during the observation period (Figure 2B, Table 3). For relative assessment of vessel dimensions and to account for systematic variations in measurements, the retinal artery-venous-ratio (AVR) was also calculated. As illustrated in Figure 2C, the AVR showed very similar changes, although the difference to the control subjects only reached statistical significance during the early phase (d0–4, p = 0.0396) and after more than 6 weeks (t/u, p = 0.0050).

**Neurovascular Coupling**

Dynamic retinal vessel analysis revealed dramatic and sustained impairments in the arterial response of aSAH patients to flicker light stimulation when compared to the control subjects (Figure 3A). In particular, aSAH patients exhibited an acute reduction in arterial vasodilation during the flicker, as reflected in a significantly lower MAD [2.2 (1.0–3.2)% vs. 3.8 (2.6–5.6)% in control subjects, p = 0.0016] and AUCart [21.5 (9.4–35.8)% vs. 51.4 (32.5–69.7)% in control subjects, p = 0.0001] during the early phase (d0–4, Figures 3B, C), while the timing of the response (i.e., tMAD and tMAD30) appeared to be largely unaffected (Table 2). Unlike the changes in arterial diameter and AVR, both MAD and AUCart showed a gradual recovery toward healthy controls, with a significant reduction only during the first 3 weeks after the ictus (Figures 3B, C). For example, AUCart increased to 22.4 [12.6–45.0]% (p < 0.0001 vs. Control) during the critical (d5–15) and 30.5 [3.2–53.9]% (p = 0.0033 vs. Control) during the late (d16–23) phase (Figure 3C). In measurements performed at follow-up more than 6 weeks after the ictus, AUCart already amounted to 44.5 [23.2–61.1]% (p = 0.0066) and critical [22.4 (12.6–45.0)% (p = 0.0047) phase (Figure 3C).
Analysis of venous responses to flicker light revealed much less marked differences (Figure 3D, Table 3). In particular, neither MVD (Figure 3E) nor the timing of venous responses (Table 3) showed significant differences compared to control subjects. Moreover, there was only a tendency for $\text{AUC}_{\text{ven}}$ during the early phase to be reduced when compared to control subjects.
Subgroup Analyses With Regard to Cardiovascular Risk Factors

Cardiovascular risk factors like diabetes mellitus have been shown to alter retinal vessel diameters and/or responses to stimulation (32) and could thus act as important confounding factors. There was only one patient with diabetes in our study, excluding further analysis of its potential as a confounding factor. However, to address the role of other cardiovascular risk factors like arterial hypertension, obesity and smoking, we examined their potential association with RVA parameters determined during the early phase. There was no difference in any of the parameters between patients stratified according to smoking status, but a tendency for AUC \text{ven} to be lower in patients in hypertension \[36.1 (12.8–43.2)\%s \text{\ vs.} 44.4 (27.6–56.5)\%s\] in normotensive patients, \(p = 0.0818\), which may have contributed to the difference in AUC \text{ven} between aSAH and control patients during the early phase described above. In addition, while AUC \text{art} tended to be lower in patients with BMI \(\geq 30\) \[8.1 (−10.1–12.5)\%s \text{\ vs.} 26.9 (11.6–36.6)\%s\] in patients with BMI < 30, \(p = 0.062\), it actually tended to be higher in patients with arterial hypertension \[27.8 (14.9–44.8)\%s \text{\ vs.} 11.9 (4.1–32.0)\%s\] in normotensive patients, \(p = 0.0502\), although none of these differences reached statistical significance (for details see Supplementary Table 1).

Subgroup Analyses With Regard to DCI and Long-Term Clinical Outcome

To examine if differences in retinal vessel responses could facilitate early detection of patients at risk of complications and delayed brain injury, we also analyzed data stratified according to the occurrence of DCI and long-term clinical outcome. While most parameters were independent of the subgroup (Supplementary Tables 2, 3), there were some subtle but significant kinetic differences between arterial responses in patients with and without DCI. In particular, patients that developed DCI showed faster vasodilation on flicker initiation during the early phase (Figure 4A), which was most evident when the average responses in both groups were normalized by their maximum amplitude (inset and arrow in Figure 4A). Quantitatively, this difference was reflected in a significantly lower tMAD\text{30} \[4.0 (3.0–6.8)\ s \text{\ in patients with DCI (n = 10) vs.} 7.0 (5.0–8.0)\ s \text{\ (p = 0.022)}\] in patients without DCI \(n = 13\). There was also a tendency for a lower tMAD in patients with DCI, but the difference was much less pronounced and did not reach statistical significance \(p = 0.254\), Figure 4C). Interestingly, these differences appeared to be restricted to the early phase and their direction actually reversed during the late phase (Figure 4D), where patients with DCI exhibited a higher tMAD\text{30} \[24.0 (21.0–29.3) s, n = 6 \text{\ vs.} 18.0 (14.0–21.0)\ s \text{\ in patients without DCI, n = 17, p = 0.017\, Figure 4F\]. In contrast, no significant differences were observed in venous retinal vessel parameters between patients with and without DCI.
arterial and venous diameters throughout the whole observation period (Supplementary Table 3), and the CRVE in these patients during the critical phase \( [d_{5–15}: 171 (144–187) \text{ MU}, n = 4] \) was significantly \( (p = 0.045) \) lower than the corresponding value in patients with a favorable outcome \( [199 (170–220) \text{ MU}, n = 43] \). Arterial and venous parameters from dynamic retinal vessel analysis on the other hand either showed no significant differences or the number of patients with a poor outcome was simply too small for statistical testing (Supplementary Table 3).

### Effects of Nimodipine Treatment

Finally, to examine if retinal vessel diameters or their response to flicker stimulation were affected by treatment with the L-type Ca\(^{2+}\) channel antagonist nimodipine, we compared data obtained during nimodipine treatment and data obtained while no nimodipine was administered (Supplementary Table 4). However, neither static nor dynamic retinal vessel parameters appeared to be affected by nimodipine. For example, in 51 static measurements performed during nimodipine treatment, arterial and venous diameters (CRAE & CRVE) were 158 [136–174] MU and 199 [171–214] MU, while the corresponding values in 30 measurements performed while no nimodipine was administered were 162 [133–178] MU (\( p = 0.4868 \)) and 200 [174–209] MU (\( p = 0.9692 \)). Likewise, maximum arterial and venous dilation upon stimulation (MAD and MVD) amounted to 2.2 [1.4–3.6]% and 3.6 [2.6–5.0]% during nimodipine treatment as compared to 2.9 [1.2–4.6]% (\( p = 0.4343 \)) and 3.7 [2.4–4.7]% (\( p = 0.8484 \)) in measurements performed while no nimodipine was administered (Figures 5A,B, for remaining parameters see Supplementary Table 4). Similar results were obtained when the same analysis was performed after stratification of the patients according to the occurrence of DCI (see Supplementary Table 4). Finally, to ensure that this was not due to differences in the time-frame of measurements performed with and without nimodipine treatment, we also compared data obtained during early, critical and late phase respectively (Figures 5C–H, Supplementary Table 6). However, neither retinal vessel diameters (Figures 5C,D), nor the maximum amplitude (Figures 5E,F), AUC (Supplementary Table 6), or time-course (Figures 5G,H) of vasodilation in response to flicker light stimulation during any of the phases appeared to be affected by nimodipine treatment.

### DISCUSSION

The exact pathophysiological cascades underlying delayed cerebral ischemia (DCI) and other complications in aSAH patients surviving the initial bleed are still poorly understood. Evidence from animal models indicates that a mismatch between metabolic demand and local CBF due to impaired NVC could contribute to DCI, but the clinical relevance of these findings has remained elusive as there is still a lack of methods for non-invasive assessment of NVC in human subjects. A promising approach to evaluate NVC in aSAH patients is to measure microvascular responses in the retina, an embryological part of the central nervous system and possibly exposed to the same vasoactive hemoglobin metabolites and inflammatory cytokines as small cerebral vessels. Thus, recent discovery of a cerebral and retinal lymphatic system indicates that there are perivascular pathways through which vasoactive agents formed in the subarachnoid space could directly reach the retinal microvasculature. Here, we used static and dynamic retinal vessel analysis (RVA) in aSAH patients to detect changes in basal diameter and responsiveness of retinal vessels to flicker light stimulation, both of which have been proposed as potential candidates for early detection of cerebrovascular dysfunction (14, 15).
TABLE 2 | Arterial RVA parameters in control and aSAH patients.

| Parameter | Median [q1–q3] | n   | p-value (vs. Control) | p-value (vs. aSAH f/u) |
|-----------|----------------|-----|---------------------|----------------------|
| CRAE [MU] |                |     |                     |                      |
| Control   | 192 [184–197]  | 42  | –                   | –                    |
| aSAH d0−4 | 157 [137–175]  | 32  | <0.0001             | 0.2214               |
| aSAH d5−15| 158 [136–174]  | 53  | <0.0001             | 0.3996               |
| aSAH d16−23| 157 [131–174]  | 23  | <0.0001             | 0.5614               |
| aSAH f/u | 164 [148–177]  | 40  | –                   | –                    |
| AVR       |                |     |                     |                      |
| Control   | 0.85 [0.82–0.89]| 42  | –                   | –                    |
| aSAH d0−4 | 0.80 [0.73–0.89]| 32  | 0.0396              | 0.8626               |
| aSAH d5−15| 0.82 [0.75–0.89]| 53  | 0.0802              | 0.4305               |
| aSAH d16−23| 0.83 [0.75–0.86]| 23  | 0.0988              | 0.7186               |
| aSAH f/u | 0.82 [0.75–0.87]| 40  | –                   | –                    |
| MAD [%]   |                |     |                     |                      |
| Control   | 3.8 [2.6–5.6]  | 42  | –                   | –                    |
| aSAH d0−4 | 2.2 [1.0–3.2]  | 32  | 0.0016              | 0.0521               |
| aSAH d5−15| 2.1 [1.4–3.6]  | 53  | 0.0002              | 0.0321               |
| aSAH d16−23| 2.9 [1.6–4.2]  | 23  | 0.0189              | 0.2623               |
| aSAH f/u | 3.0 [2.0–5.0]  | 40  | –                   | –                    |
| tMAD [s]  |                |     |                     |                      |
| Control   | 19.0 [17.0–21.0]| 42  | –                   | –                    |
| aSAH d0−4 | 17.0 [14.0–22.0]| 32  | 0.2638              | 0.6574               |
| aSAH d5−15| 18.0 [14.8–19.8]| 53  | 0.1295              | 0.7246               |
| aSAH d16−23| 20.0 [17.3–21.8]| 23  | 0.7620              | 0.0907               |
| aSAH f/u | 18.0 [12.3–20.0]| 40  | –                   | –                    |
| tMAD30 [s]|                |     |                     |                      |
| Control   | 5.0 [4.1–5.5]  | 42  | –                   | –                    |
| aSAH d0−4 | 5.0 [4.0–6.0]  | 32  | 0.1762              | 0.0266               |
| aSAH d5−15| 5.0 [3.0–7.0]  | 53  | 0.8565              | 0.1599               |
| aSAH d16−23| 5.0 [3.0–6.0]  | 23  | 0.8524              | 0.3451               |
| aSAH f/u | 4.0 [2.5–5.5]  | 40  | –                   | –                    |
| AUCart [%*s] |            |     |                     |                      |
| Control   | 51.4 [32.5–69.7]| 42  | –                   | –                    |
| aSAH d0−4 | 21.5 [9.4–35.8]| 32  | 0.0001              | 0.0066               |
| aSAH d5−15| 22.4 [12.6–45.0]| 53  | <0.0001             | 0.0047               |
| aSAH d16−23| 30.5 [3.2–53.9]| 23  | 0.0033              | 0.0890               |
| aSAH f/u | 44.5 [23.2–61.1]| 40  | 0.1380              | –                    |

AUCart, arterial area under the curve during flicker stimulation; AVR, arterial arterio-venous-ratio; CRAE, central retinal arterial equivalent; f/u, follow-up (>6 weeks after ictus); MAD, maximum arterial dilation; RVA, retinal vessel analysis; tMAD, time to maximum arterial dilation; tMAD30, time to 30% of maximum arterial dilation. Bold values indicate p < 0.05.

arterial narrowing by vasoactive substances after aSAH leads to tissue damage and structural changes with an associated long-term alteration of the arterial tone (38, 39). In this context, it is also interesting to note that perivascular enlargement in the brain, a putative imaging biomarker for microvascular brain damage (40), has recently been demonstrated to be associated with narrower arterial calibers in the retina (41).

**Dynamic RVA and Neurovascular Coupling After aSAH**

Adequate NVC is critical for continuous adjustment of local CBF to regionally heterogeneous changes in metabolic demand but may be compromised by the pathophysiological cascades initiated during bleeding into the subarachnoid space. Our present findings demonstrate a sustained decrease of retinal arterial vasodilation with partial recovery in response to flicker light stimulation in aSAH patients, as reflected in a significantly reduced maximum amplitude and area under the response curve compared to control subjects. Unlike the changes in vessel diameters, arterial responsiveness in aSAH patients showed a gradual recovery during the first 3 weeks and reached almost normal levels at follow-up more than 6 weeks after the ictus. Given that complications like DCI and DCI-related infarctions, which have been proposed to be the result of microvascular...
dysfunction in the brain, are typically restricted to the first two or at most 3 weeks after the ictus as well, these findings support the assumption that retinal vessels could serve as a surrogate marker for changes in cerebral small vessels after aSAH. The observed time-course also matches the pathophysiological cascades traditionally thought to be responsible for vascular dysfunction after aSAH, namely hemolysis of subarachnoid blood and intrathecal immune activation during the early phase, secondary immune infiltration and formation of various vasoactive hemoglobin metabolites during the critical phase and their gradual clearance during the late phase (42–44). Further support for the idea comes from recent discovery of cerebral and retinal glymphatic systems (22), which could provide a perivascular pathway through which vasoactive agents formed during the critical phase reach the retinal microvasculature. If this turns out to be the case, dynamic RVA could not only provide a unique tool to monitor their impact on microvascular function in a relatively simple manner but also a read-out of disease- or treatment-related changes in cerebral small vessels that are otherwise difficult or impossible to assess directly and

### Table 3: Venous RVA parameters in control and aSAH patients.

| Parameter | Median [q1-q3] | n | p-value (vs. Control) | p-value (vs. aSAH/f/u) |
|-----------|---------------|---|-----------------------|------------------------|
| **CRVE [MU]** | | | | |
| Control | 224 [218–236] | 42 | – | – |
| aSAHd0−4 | 196 [177–214] | 32 | –0.0001 | 0.2909 |
| aSAHd15−15 | 194 [169–217] | 53 | –0.0001 | 0.4043 |
| aSAHd23−23 | 191 [173–214] | 23 | –0.0001 | 0.2454 |
| aSAHf/u | 198 [181–209] | 40 | –0.0001 | – |
| **AVR** | | | | |
| Control | 0.85 [0.82–0.89] | 42 | – | – |
| aSAHd0−4 | 0.80 [0.73–0.89] | 32 | 0.0396 | 0.8626 |
| aSAHd15−15 | 0.82 [0.75–0.89] | 53 | 0.0802 | 0.4305 |
| aSAHd23−23 | 0.83 [0.75–0.86] | 23 | 0.0986 | 0.7186 |
| aSAHf/u | 0.82 [0.75–0.87] | 40 | 0.0050 | – |
| **MVD [%]** | | | | |
| Control | 3.9 [3.0–5.8] | 42 | – | – |
| aSAHd0−4 | 3.7 [2.9–4.7] | 32 | 0.3179 | 0.1432 |
| aSAHd15−15 | 4.1 [2.7–5.2] | 53 | 0.4165 | 0.2388 |
| aSAHd23−23 | 4.3 [2.6–5.4] | 23 | 0.6356 | 0.5304 |
| aSAHf/u | 4.5 [3.4–5.4] | 40 | 0.7270 | – |
| **tMVD [s]** | | | | |
| Control | 20.5 [19.0–22.0] | 42 | – | – |
| aSAHd0−4 | 22.0 [20.0–24.0] | 32 | 0.1872 | 0.0235 |
| aSAHd15−15 | 21.0 [19.0–22.5] | 53 | 0.9903 | 0.0761 |
| aSAHd23−23 | 22.0 [20.0–24.0] | 23 | 0.4663 | 0.0110 |
| aSAHf/u | 19.0 [18.0–22.0] | 40 | 0.2040 | – |
| **tMVD30 [s]** | | | | |
| Control | 7.0 [6.0–8.4] | 42 | – | – |
| aSAHd0−4 | 6.0 [5.0–6.0] | 32 | 0.1269 | 0.6026 |
| aSAHd15−15 | 7.0 [6.0–8.0] | 53 | 0.7015 | 0.3347 |
| aSAHd23−23 | 7.0 [7.0–8.0] | 23 | 0.0720 | 0.1297 |
| aSAHf/u | 6.5 [5.5–7.0] | 40 | 0.1530 | – |
| **AUCven [%*s]** | | | | |
| Control | 45.7 [31.3–62.2] | 42 | – | – |
| aSAHd0−4 | 41.3 [16.4–46.8] | 32 | 0.0610 | 0.0205 |
| aSAHd15−15 | 45.0 [27.5–60.8] | 53 | 0.3833 | 0.1464 |
| aSAHd23−23 | 44.5 [20.2–60.9] | 23 | 0.3064 | 0.1853 |
| aSAHf/u | 52.4 [34.2–61.7] | 40 | 0.6030 | – |

AUC<sub>ven</sub>, venous area under the curve during flicker stimulation; AVR, retinal arterio-venous-ratio; CRVE, central retinal venous equivalent; f/u, follow-up (>6 weeks after ictus); MVD, maximum venous dilation; RVA, retinal vessel analysis; tMVD, time to maximum venous dilation; tMVD<sub>30</sub>, time to 30% of maximum venous dilation. Bold values indicate p < 0.05.
non-invasively. For example, our present findings suggest that nimodipine, the only FDA-approved pharmacological treatment for delayed cerebral vasospasm after aSAH (45), neither affects the basal diameter nor the responsiveness of retinal microvessels to stimulation, although this remains to be confirmed in future studies.

Likewise, further study will be required to evaluate the sensitivity of RVA with regard to the early detection of DCI.
Limitations and Confounding Factors
There are several confounding factors that have to be taken into account when interpreting our results. First and foremost, although adaptation of our current imaging technique allowed us to also recruit some more severely affected, analgo-sedated patients, cases with mild aSAH, good clinical grade (HH1−3), and/or good clinical outcome were still clearly overrepresented in our cohort, which may have biased the observed changes, likely toward milder alterations. To overcome this limitation, which is mainly brought about by the limited maneuverability of the required funduscope in supine patients, we are currently working on a miniaturized, wearable device for RVA that is comparable to commercially available “smartglasses” and should facilitate bedside testing of immobilized and sedated patients (46). That said, given the complexity of blood flow regulation and NVC, it is likely that numerous factors, some of which may still be unknown, can influence retinal vessel diameters and their responsiveness to stimulation. In order to reduce potential confounding factors and ensure standardized, physiological conditions at the time of image acquisition, our measurements were routinely paralleled by multimodal monitoring of mean arterial blood pressure (MAP), heart rate, blood gases, oxygenation, and intracranial pressure (ICP). In addition, our analysis indicates that there was no effect of nimodipine treatment on any of the parameters evaluated. With regard to static RVA, it is also important to keep in mind that direct comparison of CRAE and CRVE values between control and aSAH patients may have been influenced by the fact that measurements were performed using devices at two different facilities.

It is also worth noting that cardiovascular risk factors like diabetes or arterial hypertension could act as confounding
Dependence of retinal vessel properties in aSAH patients on nimodipine treatment. (A) Average relative arterial responses to flicker light stimulation measured with or without nimodipine (nimo) treatment. Inset shows the same data but scaled to the same amplitude for comparison of response kinetics. Stimulation period is indicated by light gray shading. (B) Average relative venous responses to flicker light stimulation measured with or without nimodipine (nimo) treatment. Inset shows the same data but scaled to the same amplitude for comparison of response kinetics. Stimulation period is indicated by light gray shading. (C–H) Comparison of (C) central retinal arterial equivalent (CRAE), (D) central retinal venous equivalent (CRVE), (E) maximum arterial dilation (MAD), (F) maximum venous dilation (MVD), (G) time to 30 and 100% of maximum arterial dilation (tMAD30 & tMAD), and (H) time to 30 and 100% of maximum venous dilation (tMVD30 & tMVD) in aSAH patients with or without nimodipine treatment during the early (aSAHd0−4), critical (aSAHd5−15), and late (aSAHd16−23) phase.

Factors and complicate the use of RVA in the context of aSAH. For example, in the present study, there was a tendency for AUCart to be higher in patients with arterial hypertension, which could partly mask the decrease of this parameter after aSAH. Consistent with previous studies (32), these differences were relatively subtle and they did not reach statistical significance, but further studies on the role of these and other cardiovascular risk factors will clearly be required before RVA can be reliably used for diagnostic applications in the context of aSAH.
Finally, it should be noted that in contrast to our previous study, we observed no significant effects of aSAH on the latency of arterial or venous responses, which could reflect the fact that these parameters are more sensitive to inherent technical limitations such as the finite signal-to-noise ratio. As such, our present findings that patients with DCI exhibit a reduced arterial latency (tMAD$_{30}$) during the early but increased arterial latency (tMAD) during the late phase should be interpreted with care as well-until they can be confirmed in future studies.

In particular, given the subtle nature of these differences, it seems unlikely that they would allow for reliable prediction and/or confirmation of DCI in the clinical setting. However, based on the small number of patients we evaluated, future studies with larger patient populations may be able to identify more robust correlations between RVA parameters and DCI. Considering that DCI remains one of the main preventable causes of poor clinical outcomes after aSAH, such studies will almost certainly be performed in the near future and their results should help to conclusively rate the clinical value of RVA in this setting.

**CONCLUSIONS**

Our findings confirm and extend the results from previous studies that aSAH is associated with sustained vasoconstriction and impairments of NVC in retinal vessels. Retinal vessel responses may differ between patients with and without DCI. Although their clinical relevance remains to be firmly established, these findings suggest that RVA could be a unique tool for monitoring microvascular function in aSAH patients in a simple and non-invasive manner.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**REFERENCES**

1. Kapitan GJ, Lanzino G, Kassell NF. Subarachnoid hemorrhage: epidemiology, risk factors, and treatment options. *Drugs Aging.* (2000) 17:183–99. doi: 10.2165/00002512-200017030-00003
2. Weaver JP, Fisher M. Subarachnoid hemorrhage: an update of pathogenesis, diagnosis and management. *J Neurol Sci.* (1994) 125:119–31. doi: 10.1016/0022-510X(94)90024-8
3. Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, van Gijn J. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke.* (2010) 41:2391–5. doi: 10.1161/STROKEAHA.110.589275
4. Meyers PM, Connolly ES. Disappointing results for clazosentan in CONSCIOUS-2. *Nat Rev Neurol.* (2011) 7:660–1. doi: 10.1038/nrneurol.2011.168
5. Naraoka M, Matsuda N, Shimamura N, Asano K, Okhuma H. The role of arterioles and the microcirculation in the development of vasospasm after aneurysmal SAH. *Biomed Res Int.* (2014) 2014:253746. doi: 10.1155/2014/253746

**ETHICS STATEMENT**

All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Reference Number EK 069/15. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

WA, CC, MWe, KS, DK, and GS: conceived, designed, and performed the experiments. WA: first drafting of the manuscript. WA and FN: illustrations. WA, CC, MWe, KS, KK, and GS: data acquisition. WA, CC, KK, and GS: analysis and interpretation of data. WA, CC, TS, JH, AB, AS-T, FN, MWi, HC, and GS: critical review of the manuscript. All authors were critically revised and approved by the final manuscript.

**FUNDING**

WA was supported by funding from the German Society of Neurointensive and Emergency Medicine (Junior research award 2017). CC was supported by the START-Program of the Faculty of Medicine (RWTH Aachen University, Grant No. 691545) and by the Foundation of Neurosurgical Research (German Society of Neurosurgery, 2016).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2021.690183/full#supplementary-material

6. Geraghty JR, Davis JL, Testai FD. Neuroinflammation and microvascular dysfunction after experimental subarachnoid hemorrhage: emerging components of early brain injury related to outcome. *Neurocrit Care.* (2019) 31:373–89. doi: 10.1007/s12028-019-00710-x
7. Suzuki H, Kanamaru H, Kawakita F, Asada R, Fujimoto M, Shiba M. Cerebrovascular pathophysiology of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. *Histol Histopathol.* (2021) 36:143–58. doi: 10.14670/HH-18-253
8. Balbi M, Koida M, Wellman GC, Plesnila N. Inversion of neurovascular coupling after subarachnoid hemorrhage in vivo. *J Cereb Blood Flow Metab.* (2017) 37:3625–34. doi: 10.1177/0271678X16686595
9. Balbi M, Vega MJ, Lourbopoulos A, Terpolilli NA, Plesnila N. Long-term impairment of neurovascular coupling following experimental subarachnoid hemorrhage. *J Cereb Blood Flow Metab.* (2020) 40:1193–202. doi: 10.1177/0271678X19863021
10. Koide M, Bonev AD, Nelson MT, Wellman GC. Inversion of neurovascular coupling by subarachnoid blood depends on large-conductance Ca2+-activated K+ (BK) channels. *Proc Natl Acad Sci USA.* (2012) 109:E1387–95. doi: 10.1073/pnas.1121359109
11. Conzen C, Albanna W, Weiss M, Kürtén D, Vilser W, Kotliar K, et al. Vasocostriction and impairment of neurovascular coupling after subarachnoid hemorrhage: a descriptive analysis of retinal changes. *Transl Stroke Res.* (2018) 9:284–93. doi: 10.1007/s12975-017-0358-8

12. Winkler MKL, Chassidim Y, Lublinsky S, Revankar GS, Major S, Karg E-J. Impaired neurovascular coupling to ischaemic epileptic activity and spreading depolarization in a patient with subarachnoid hemorrhage: possible link to blood-brain barrier dysfunction. *Epilepsia.* (2012) 53:22–30. doi: 10.1111/j.1528-1167.2012.03699.x

13. da Costa L, Fierstra J, Fisher JA, Mikulis DJ, Han JS, Tymianski M. BOLD MRI and early impairment of cerebrovascular reserve after aneurysmal subarachnoid hemorrhage. *J Magn Reson Imaging.* (2014) 40:972–9. doi: 10.1002/jmri.24474

14. Cabrera DeBuc D, Somfai GM, Koller A. Retinal microvascular network alterations: Potential biomarkers of cerebrovascular and neural diseases. *Am J Physiol Circ Physiol.* (2017) 312:H201–12. doi: 10.1152/ajpheart.00201.2016

15. Patton N, Aslam T, MacGillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvascularities. *J Anat.* (2005) 206:319–48. doi: 10.1111/j.1469-7580.2005.00395.x

16. Lipeza A, Csipo T, Tarantini S, Hand RA, Ngo BTN, Conley S, et al. Age related impairment of neurovascular coupling responses: a dynamic vessel analysis (DVA)-based approach to measure decreased flicker light stimulus-induced retinal arterial dilation in healthy older adults. *GeroScience.* (2019) 41:341–9. doi: 10.1007/s11357-019-00078-y

17. Golzan SM, Goozee K, Georgevsky D, Avolio A, Chatterjee P, Shen K, et al. Vasoconstriction and impairment of neurovascular coupling in the subarachnoid hemorrhage cerebral vasospasm. *Front Neurol.* (2017) 8:669. doi: 10.3389/fneur.2017.00669

18. Heitmar R, Lip GYH, Ryder RE, Blann AD. Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease. *Cardiovasc Diabetol.* (2017) 16:56. doi: 10.1186/s12933-017-0534-6

19. Bederson JB, Levy AL, Hong Ding W, Kahn R, DiPerna CA, Jenkins AJ, et al. Acute vasoconstriction after subarachnoid hemorrhage. *Neurosurgery.* (1998) 42:352–62. doi: 10.1093/neuros/42.10.99802000-00991

20. Weir B, Grace M, Hansen J, Roithberg C. Time course of vasospasm in man. *J Neurosurg.* (1978) 48:173–8. doi: 10.3171/jns.1978.48.2.0173

21. Ferguson S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery.* (2007) 60:658–67. doi: 10.1227/01.NEU.0000255396.23280.31

22. Liu Z, Li Q, Cui G, Zhu G, Tang W, Zhao H, et al. Blood-filled cerebrospinal fluid-enhanced pericyte microvasculature contraction in rat retina: a novel in vitro study of subarachnoid hemorrhage. *Exp Ther Med.* (2016) 12:2411–6. doi: 10.3892/etm.2016.3644

23. Wang KC, Tang SC, Lee JE, Tsai JC, Lai DM, Lin WC, et al. Impaired microcirculation after subarachnoid hemorrhage in an in vivo animal model. *Sci Rep.* (2018) 8:13315. doi: 10.1038/s41598-018-31709-7

24. Vorkapic P, Bevan JA, Bevan RD. Longitudinal in vivo and in vitro time-course study of chronic cerebrospinal fluid flow in the rabbit basilar artery. *Neurosurg Rev.* (1991) 14:215–9. doi: 10.1007/BF00301660

25. Pooyush Kumar T, McBride DW, Dash PK, Matsumura K, Rabi A, Blackburn SL. Endothelial cell dysfunction and injury in subarachnoid hemorrhage. *Mol Neurobiol.* (2019) 56:1992–2006. doi: 10.1007/s12035-018-1213-7

26. Groeschel S, Chong WK, Surtees R, Hanefeld F. Virchow-Robin spaces on magnetic resonance images: normative data, their dilatation, and a review of the literature. *Neuroradiology.* (2006) 48:745–754. doi: 10.1007/s00234-006-0112-1

27. Mutlu U, Adams HHH, Hofman A, Lutj A van der, Klaver CCW, Vernooij MW, et al. Retinal microvascular calibers are associated with enlarged perivascular spaces in the brain. *Stroke.* (2016) 47:1374–6. doi: 10.1161/STROKEAHA.115.012438

28. Clark JF, Sharp FR. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. *J Cereb Blood Flow Metab.* (2006) 26:1223–33. doi: 10.1089/jcbfm.96.00280

29. Kikuchi T, Okuda Y, Kaito N, Abe T. Cytokine production in cerebrospinal fluid after subarachnoid haemorrhage. *Neurol Res.* (1995) 17:106–8. doi: 10.1080/0161141.1995.1170296

30. Roa JA, Sarkar D, Zanaty M, Ishii D, Lu Y, Karandikar NJ, et al. Preliminary results in the analysis of the immune response after aneurysmal subarachnoid hemorrhage. *Sci Rep.* (2020) 10:11809. doi: 10.1038/s41598-020-6881-y
45. Maruhashi T, Higashi Y. An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage. Expert Opin Pharmacother. (2021) 1–14. doi: 10.1080/14656666.2021.1912013

46. Albanna W. Retinal vessel analysis for acute neurovascular diseases: timely realization of a wearable prototype by unorthodox means. Int J Ophthalmic Pathol. (2019) 8.

Conflict of Interest: IMEDOS Systems GmbH provided the Retinal Vessel Analyzer for research purposes only. The company did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Albanna, Conzen, Weiss, Seyfried, Kotliar, Schmidt, Kuerten, Hocheler, Bruecken, Schmidt-Trucksäss, Neumaier, Wiesmann, Clusmann and Schubert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.